Quanticate

Executive Summary

Quanticate is a leading global Biometrics Contract Research Organisation (CRO) headquartered in the UK, with over 30 years of experience providing statistical analysis, data management, and clinical trial reporting to pharmaceutical and biotechnology companies. The company specializes in ensuring data integrity and regulatory compliance across all phases of clinical development, leveraging a deep heritage in the industry. As a private firm with no disclosed funding, Quanticate operates independently, focusing on delivering high-quality biometrics services. The increasing complexity of clinical trials and the growing need for robust data analytics present significant opportunities for the company to expand its client base and deepen existing relationships. Looking ahead, Quanticate is well-positioned to capitalize on the outsourcing trend among pharma companies seeking to reduce costs and accelerate timelines. The company's presence in the AI/Machine Learning category suggests potential for innovation in trial data analytics, which could drive differentiation. Key catalysts for the company include securing major contracts with large pharmaceutical firms, launching AI-enhanced analytics platforms, and expanding geographically, particularly in the US market. While no specific catalysts have been publicly announced, the company's established reputation and specialized focus provide a strong foundation for growth.

Upcoming Catalysts (preview)

• Q3 2026Major contract win with large pharmaceutical company40% success
• Q4 2026Launch of AI-powered clinical data analytics platform50% success
• 2027Expansion into the US market through strategic partnership30% success